Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy
Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T
Published in Vascular Health and Risk Management
Methodology
Triple-blinded, placebo- and diet-controlled randomised trial of pantethine 600-900 mg daily for 16 weeks in adults eligible for statin therapy.
Key Findings
Pantethine lowered total, LDL and non-HDL cholesterol by roughly 4-11% versus placebo with no significant adverse events.
Conclusions
Pantethine produces modest lipid lowering, far smaller than statin therapy, but may suit low-risk or statin-intolerant patients.
Limitations
Modest sample, industry involvement, short duration, no clinical event endpoints.
Supplements Studied
Pantethine favorably altered total, LDL and non-HDL cholesterol in subjects eligible for statin therapy.
Outcomes Measured
Pantethine favorably altered total, LDL and non-HDL cholesterol versus placebo.
Pantethine lowered total, LDL and non-HDL cholesterol by roughly 4-11% versus placebo with no significant adverse events.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.